← Back to Search

Hormone Therapy

Androgen Receptor Antagonists for Prostate Cancer

Phase < 1
Recruiting
Led By David Einstein, MD
Research Sponsored by Beth Israel Deaconess Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Testosterone >100 ng/dL within 6 months prior to enrollment with no intervening hormonal therapies
Assigned by treating physician to receive standard-of-care AR antagonist monotherapy using FDA-approved apalutamide, darolutamide, or enzalutamide
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4
Awards & highlights

Study Summary

This trial will explore if hormonal therapies can increase PSMA levels in recurrent prostate cancer patients via PET/CT scans. 15 participants will receive androgen receptor antagonist monotherapy for 4 weeks.

Who is the study for?
Men aged 40+ with prostate cancer previously treated but now showing rising PSA levels indicating recurrence. They must have a PSMA PET/CT scan suggesting recurrent cancer, normal testosterone levels, and be prescribed standard AR antagonist therapy (apalutamide, darolutamide, or enzalutamide) by their doctor.Check my eligibility
What is being tested?
This study tests if early hormonal therapies increase PSMA detected by PET/CT scans in men with recurring prostate cancer. About 15 participants will receive standard AR antagonist monotherapy and undergo PSMA level measurements for approximately 4 weeks.See study design
What are the potential side effects?
Possible side effects of the AR antagonists apalutamide, darolutamide, and enzalutamide include fatigue, high blood pressure, skin rash, falls or fractures due to bone weakness; digestive issues like nausea or diarrhea; and potential liver problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check β€œYes” for the criteria below
Select...
My testosterone level was above 100 ng/dL in the last 6 months without hormone treatments.
Select...
My doctor has prescribed me a specific prostate cancer medication.
Select...
My scan shows at least one area that might mean my prostate cancer has come back.
Select...
I am over 40, had prostate cancer treatment, and my PSA levels are rising.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of Participants with New Lesions (Flare)
Secondary outcome measures
Changes in serum PSA
Changes in tumor SUV
Changes in tumor size

Trial Design

1Treatment groups
Experimental Treatment
Group I: Androgen Receptor Antagonist MonotherapyExperimental Treatment2 Interventions
Participants will receive pre-determined doses of apalutamide, darolutamide, or enzalutamide per standard care. Participants will undergo Prostate-Specific Membrane Antigen (PSMA) PET/CT scans at weeks 1 and 4.

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteOTHER
1,078 Previous Clinical Trials
340,858 Total Patients Enrolled
Beth Israel Deaconess Medical CenterLead Sponsor
836 Previous Clinical Trials
13,010,310 Total Patients Enrolled
David Einstein, MDPrincipal InvestigatorBeth Israel Deaconess Medical Center
1 Previous Clinical Trials

Media Library

Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi] (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05683964 β€” Phase < 1
Prostate Adenocarcinoma Research Study Groups: Androgen Receptor Antagonist Monotherapy
Prostate Adenocarcinoma Clinical Trial 2023: Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi] Highlights & Side Effects. Trial Name: NCT05683964 β€” Phase < 1
Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi] (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05683964 β€” Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the recruitment process for this trial still underway?

"The current status of this medical study, as reported on clinicaltrials.gov is that it has concluded its participant recruitment phase. The trial was first posted in January 1st 2023 and updated most recently on April 1st 2023 - though other trials are available for those seeking to participate at this point in time, with 2,224 currently active studies recruiting patients."

Answered by AI
~4 spots leftby Sep 2024